For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$7.56
Thesis
Absci pairs generative AI antibody design with integrated wet-lab validation to create and optimize biologics. The platform aims to compress discovery timelines through both internal programs and pharma partnerships.
Catalysts
- Lead candidate progression toward the clinic
- New AI antibody-design partnerships
- Validation of generative design against conventional discovery
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 24Securities offeringSEC
Absci files 424B5 prospectus supplement.
- Jun 24OtherSEC
Absci filed 8-K item 8.01 (other events) on 2026-06-24.
- Jun 24DealSEC
8-K filed disclosing entry into material definitive agreement (items 1.01/8.01/9.01).
- May 7Financial resultsSEC
Absci filed 8-K (items 2.02,8.01,9.01) disclosing results of operations and financial condition.